公开(公告)号：US11932693B2

公开(公告)日：2024-03-19

申请号：US18315686

申请日：2023-05-11

Applicant: BioNTech SE ,  Genmab A/S

Inventor： Ugur Sahin ,  Sina Fellermeier-Kopf ,  Friederike Gieseke ,  Karsten Beckmann ,  Claudia Paulmann ,  Alexander Muik ,  Ivan Kuzmanov ,  Esther Cornelia Wilhelmina Breij ,  Patricia Garrido Castro ,  Jordan Blum ,  Lars Guelen ,  Joost Neijssen ,  Bart-Jan De Kreuk ,  Richard Hibbert ,  Janine Schuurman ,  Aran Frank Labrijn

IPC: C07K16/28

CPC classification number: C07K16/2818 ,  C07K2317/24 ,  C07K2317/92

Abstract: The present disclosure relates to antibodies having the ability to bind to the immune checkpoint protein programmed death-1 (PD-1), such as human PD-1, or nucleic acids encoding such antibodies, wherein the antibodies comprise modifications in the Fc region eliminating or reducing a Fc-mediated effector function of the antibodies. The present disclosure also relates to compositions or kits comprising said antibodies or nucleic acids, as well as to the use of these antibodies or nucleic acids or compositions in the field of medicine, preferably in the field of immunotherapy, e.g., for the treatment of cancers. The present invention further relates to methods for inducing an immune response in a subject comprising providing to the subject an antibody of the present disclosure or one or more nucleic acids encoding such an antibody, or a composition comprising said antibody or nucleic acids.

公开(公告)号：US20230287088A1

公开(公告)日：2023-09-14

申请号：US18019787

申请日：2021-07-29

Applicant: BIONTECH SE

Inventor： Karsten Beckmann ,  Anna Carle ,  Sandra Prassl ,  Claudia Paulmann ,  Christiane Stadler ,  Georg Falck ,  Leyla Fischer ,  Alexander Muik ,  Ugur Sahin ,  Caroline Scharf

IPC: C07K16/10 ,  A61P31/14

CPC classification number: C07K16/10 ,  A61P31/14 ,  C07K2317/31 ,  C07K2317/92

Abstract: The present disclosure relates to a binding agent comprising a first and a second binding domain, wherein the first binding domain is capable of binding to a coronavirus spike protein (S protein) and the second binding domain is capable of binding to the coronavirus S protein, and wherein the first and second binding domains bind to different epitopes of the coronavirus S protein. Moreover, the disclosure relates to an antibody capable of binding to a coronavirus spike protein (S protein). The disclosure also relates to a nucleic acid such as RNA encoding the binding agent, in particular antibody, disclosed herein and a host cell transformed or transfected with said nucleic acid. Furthermore, the disclosure relates to a medical use of said binding agent, antibody, or nucleic acid. The agents and medical uses described herein are, in particular, useful for the prevention or treatment of coronavirus infection in a subject.